MARKET

GMAB

GMAB

Genmab
NASDAQ
26.14
-0.43
-1.62%
After Hours: 26.14 0 0.00% 16:10 03/13 EDT
OPEN
26.61
PREV CLOSE
26.57
HIGH
26.84
LOW
26.06
VOLUME
1.03M
TURNOVER
--
52 WEEK HIGH
35.43
52 WEEK LOW
17.24
MARKET CAP
16.09B
P/E (TTM)
17.02
1D
5D
1M
3M
1Y
5Y
1D
Barclays Reaffirms Their Buy Rating on Genmab A/S (0MGB)
TipRanks · 2d ago
Harbor Health Care ETF Q4 2025 Portfolio Review
Seeking Alpha · 3d ago
Genmab Updates Share Buy-Back Program and Corrects Accumulated Purchase Figures
TipRanks · 5d ago
Weekly Report: what happened at GMAB last week (0302-0306)?
Weekly Report · 6d ago
Genmab Updates Articles of Association, Expands Capital and Warrant Authorizations
TipRanks · 03/04 16:58
Genmab Ends Early‑Stage PRO1160 Cancer Trial: What It Means for GMAB Investors
TipRanks · 03/04 16:31
Simulations Plus to Host Responsible AI in MIDD Panel at ASCPT Annual Meeting
Reuters · 03/03 12:55
Genmab Corrects Insider Share Transaction Pricing in March 2 Filings
TipRanks · 03/03 11:40
More
About GMAB
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

Webull offers Genmab A/S stock information, including NASDAQ: GMAB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GMAB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GMAB stock methods without spending real money on the virtual paper trading platform.